A phase IV, unicentric, open label clinical trial to evaluate the default mode network in multiple sclerosis patients on Cladribine treatment
- Conditions
- Multiple SclerosisMedDRA version: 20.1Level: PTClassification code: 10028245Term: Multiple sclerosis Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2023-504577-21-00
- Lead Sponsor
- María Luisa Martínez Ginés
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
MS diagnostic following McDonald 2010 diagnosis criteria., Age between 30 and 55 years old., MS patients that started treatment with cladribine tablets in the last month., Consent form signature
Dementia diagnosis, following Spanish Neurological Society criteria., Mayor psychiatric illness., Physical or intellectual limitations to successfully perform neuropsychological evaluation., Any other circumstance that may interfere with functional magnetic resonance session, Abnormal renal function previous to MRI session., Pregnant or breastfeeding females or males and females of childbearing potential not willing to use a medically acceptable contraceptive method from enrolment until six months after the end of the treatment
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method